Tango Therapeutics
TNGX
170 hedge funds and large institutions have $1.53B invested in Tango Therapeutics in 2025 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 75 increasing their positions, 27 reducing their positions, and 22 closing their positions.
216% more call options, than puts
Call options by funds: $841K | Put options by funds: $266K
178% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 27
141% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 22
30% more capital invested
Capital invested by funds: $1.18B → $1.53B (+$352M)
24.09% more ownership
Funds ownership: 103.99% → 128.08% (+24%)
21% more funds holding
Funds holding: 141 → 170 (+29)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$69.8M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$36.4M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$34.8M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$33.8M |
| 5 |
CP
Caligan Partners
New York
|
+$32.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$89.3M |
| 2 |
TGI
TRV GP IV
Boston,
Massachusetts
|
-$51.6M |
| 3 |
GS
Gilead Sciences
Foster City,
California
|
-$40.8M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$26.5M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$25.9M |
TNGX Hedge Fund Activity: Q4 2025 in Review
170 of the 8,274 institutional investors tracked by Wall St. Rank reported a position in Tango Therapeutics (TNGX) for Q4 2025, worth a combined $1.53B — up 30% from $1.18B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new TNGX positions and 22 closed out — a net gain of 31 holders — while 75 added to existing stakes and 27 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $69.8M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $89.3M sold.
- 170 institutional investors held Tango Therapeutics (TNGX) as of Q4 2025, up from 141 in Q3 2025.
- Funds reported $1.53B of Tango Therapeutics stock for Q4 2025, up 30% quarter-over-quarter.
- 53 funds opened new Tango Therapeutics positions in Q4 2025 and 22 closed out, a net change of +31 holders.
- The largest Tango Therapeutics buyer in Q4 2025 was Adage Capital Partners, an estimated $69.8M added.
- The largest Tango Therapeutics seller in Q4 2025 was EcoR1 Capital, an estimated $89.3M sold.
Based on aggregated 13F filings for Q4 2025.